Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension
Authors:
- Thomas HazenootTHThomas Hazenoot
- Anco BoonstraABAnco Boonstra
- Menno V. HuismanMHMenno V. Huisman
- Anton Vonk-NoordegraafAVAnton Vonk-Noordegraaf
- 30 August 2012
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 41 (4) , 872-878
Abstract
Vitamin K antagonists are advised in pulmonary arterial hypertension patients despite a lack of safety data.We reviewed major bleeding in three classes of pulmonary hypertension patients, all receiving vitamin K antagonists.Bleeding event rates were 5.4 per 100 patient-years for patients with idiopathic pulmonary arterial hypertension, 19 per 100 patient-years for connective tissue disease related pulmonary arterial hypertension patients and 2.4 per 100 patient-years for chronic thromboembolic pulmonary hypertension patients. Life tables analysis showed that event-free survival was worse in patients with connective tissue disease related pulmonary hypertension than in patients with idiopathic pulmonary arterial hypertension (Wilcoxon=12.8; p<0.001), and patients with chronic thromboembolic pulmonary hypertension (Wilcoxon=23.2; p<0.001). Patients with idiopathic pulmonary arterial hypertension suffered more events than patients with chronic thromboembolic pulmonary hypertension (Wilcoxon=7.2; p<0.01). Major bleeding was independent of age, sex, target international normalised ratio (INR) range, documented INR, vitamin K antagonist type, or right atrial pressure, but was associated with use of prostacyclin analogues.Major bleeding risk during vitamin K antagonist therapy differs among groups of patients with pulmonary hypertension. Further research regarding optimal anticoagulant therapy is needed, as well as risk–benefit analyses for pulmonary hypertension patients with a higher bleeding propensity.Keywords
This publication has 34 references indexed in Scilit:
- Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) StudyAmerican Heart Journal, 2005
- Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillationJACC, 2004
- Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertensionJACC, 2004
- Prostanoid therapy for pulmonary arterial hypertensionJACC, 2004
- Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial FibrillationNew England Journal of Medicine, 2003
- Care of Patients Receiving Long-Term Anticoagulant TherapyNew England Journal of Medicine, 2003
- PATHOBIOLOGY OF PULMONARY HYPERTENSIONClinics in Chest Medicine, 2001
- Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary HypertensionNew England Journal of Medicine, 1998
- An Analysis of the Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Nonrheumatic Atrial FibrillationNew England Journal of Medicine, 1996
- The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary HypertensionNew England Journal of Medicine, 1992